The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, Cronin L, Green JB, Agrawal N, Arimoto R, Mayne KJ, Sammons E, Brueckmann M, Shah SV, Rossing P, Nangaku M, Landray MJ, Wanner C, Baigent C, Haynes R, Herrington WG.
Judge PK, et al. Among authors: rossing p.
Nephrol Dial Transplant. 2024 Nov 12:gfae263. doi: 10.1093/ndt/gfae263. Online ahead of print.
Nephrol Dial Transplant. 2024.
PMID: 39533115